As the field of onco-haematology is constantly, often turbulently, evolving, the promotion of meetings that allow researchers to compare and share information, transferring acquisitions obtained from the study of the genome to the bedside, is crucial and can lead to the development of innovative personalised treatments with highest therapeutic effect and lowest toxicity burden.

In this context, we believe that a discussion on the state of the art of blood and lymphatic tissue cancers could represent an important scientific, cultural and informative contribution of the national and international medical community, in the year in which the World Health Organization is preparing to publish guidelines for the - increasingly molecular - diagnosis and treatment of such conditions.